Equities

Insulet Corp

Insulet Corp

Actions
Health CareMedical Equipment and Services
  • Price (USD)264.40
  • Today's Change-2.18 / -0.82%
  • Shares traded19.47k
  • 1 Year change+45.82%
  • Beta1.2027
Data delayed at least 15 minutes, as of Nov 21 2024 14:46 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Insulet Corporation is a medical device company. It is primarily engaged in the development, manufacture and sale of its continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), the Omnipod DASH Insulin Management System, the Omnipod Insulin Management System, and Omnipod GO. It also produces pods for Amgen for use in the Neulasta Onpro kit, a delivery system for Amgen's Neulasta. The Omnipod platform offers continuous insulin delivery that provides various benefits of insulin pump therapy in a way without the need for external tubing required with conventional pumps. The small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back, and delivers insulin into the body through a small flexible tube. Omnipod 5 includes an AID algorithm embedded in the Pod.

  • Revenue in USD (TTM)1.98bn
  • Net income in USD420.90m
  • Incorporated2000
  • Employees3.00k
  • Location
    Insulet Corp100 Nagog ParkACTON 01720-3440United StatesUSA
  • Phone+1 (978) 600-7000
  • Fax+1 (978) 600-0120
  • Websitehttps://www.omnipod.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Solventum Corp8.22bn720.00m11.81bn22.01k16.423.709.341.444.164.1647.4518.480.58313.937.19373,290.305.11--6.03--56.38--8.76--0.82685.020.7176--0.8241--0.2234------
Globus Medical Inc2.48bn91.51m13.26bn5.00k125.962.7937.905.350.66360.663618.0829.940.47471.284.58495,719.201.756.901.997.4558.1471.733.6914.051.64--0.09740.0053.3417.08-35.39-4.725.57--
Revvity Inc2.72bn258.26m13.55bn11.50k53.151.7219.734.982.092.0622.0664.880.20782.894.37236,657.001.974.762.155.3955.4457.199.4915.342.9711.960.28696.52-16.95-0.1982-64.99-5.28-2.690.00
Avantor Inc6.82bn309.60m13.71bn14.50k44.332.4719.182.010.45440.454410.018.160.5325.566.09470,331.002.422.972.753.3533.5333.444.545.061.063.290.46980.00-7.263.51-51.52--31.17--
Baxter International Inc11.77bn225.00m16.65bn60.00k73.822.1212.701.410.4420.21423.1015.420.41052.915.42196,133.300.81980.19421.050.233338.4338.202.000.36741.093.810.61961,398.942.125.9497.15--0.9829.71
Align Technology, Inc.3.96bn441.57m16.71bn21.61k38.164.2428.714.225.875.8752.6352.760.62454.324.14183,272.506.9616.3410.3924.1469.9871.7211.1523.161.14--0.000.003.4214.4523.092.15-4.46--
Hologic Inc4.03bn789.50m18.13bn6.99k23.503.5316.504.503.323.3216.9722.090.44062.726.57--8.6313.129.8415.2056.2560.8219.5924.753.0364.450.3307---0.00253.6673.14--4.30--
Insulet Corp1.98bn420.90m18.70bn3.00k46.3416.7237.479.435.755.7525.9615.940.72231.426.14661,300.0015.322.7118.563.1469.3665.8121.224.282.8098.710.55570.0030.0224.664,384.78128.77-7.63--
Cooper Companies Inc3.80bn359.30m19.73bn15.00k55.182.4926.815.191.801.8019.0239.800.31961.705.56253,606.703.0210.063.2911.3466.3665.549.4529.001.185.460.24930.34698.617.24-23.74-3.6615.180.00
Illumina Inc4.39bn-1.58bn20.88bn10.59k--9.85--4.76-10.00-10.0027.6113.360.54412.666.17414,542.00-19.63-6.20-23.16-7.2863.9466.39-36.08-15.481.8538.440.4834---1.756.2173.64---7.91--
Steris PLC5.12bn602.62m20.95bn18.18k34.933.1818.924.096.084.3851.6266.800.47583.865.49281,655.405.625.196.105.6843.0143.6411.8110.971.558.290.252836.5613.2813.06-1.0712.6713.698.83
Waters Corp2.91bn622.64m21.24bn7.90k34.1413.2526.077.3110.4810.4848.8927.000.6452.204.47367,740.1013.8219.7716.7225.2959.7358.4521.4323.381.3810.110.53250.00-0.52294.09-9.261.534.72--
Zimmer Biomet Holdings Inc7.60bn1.08bn21.75bn18.00k20.811.7610.572.865.255.2536.8762.000.35380.91365.38421,972.205.052.215.822.5271.7871.2514.287.280.69877.520.342538.906.55-1.40252.86--9.440.00
West Pharmaceutical Services Inc.2.88bn499.60m22.57bn10.60k46.188.2135.597.856.756.7538.8637.960.77434.505.51271,358.5013.0215.6115.1618.6534.8738.0616.8118.472.23--0.069510.692.1811.432.2823.7628.166.20
Data as of Nov 21 2024. Currency figures normalised to Insulet Corp's reporting currency: US Dollar USD

Institutional shareholders

54.39%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Sep 20248.16m11.63%
Capital Research & Management Co. (Global Investors)as of 30 Sep 20247.77m11.09%
Fidelity Management & Research Co. LLCas of 30 Sep 20247.22m10.30%
BlackRock Fund Advisorsas of 30 Sep 20244.17m5.95%
SSgA Funds Management, Inc.as of 30 Sep 20242.91m4.16%
Baillie Gifford & Co.as of 30 Sep 20242.28m3.25%
Geode Capital Management LLCas of 30 Sep 20241.74m2.48%
ClearBridge Investments LLCas of 30 Sep 20241.47m2.10%
FIL Investments Internationalas of 30 Sep 20241.42m2.02%
William Blair Investment Management LLCas of 30 Sep 2024997.59k1.42%
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.